OTHER INFORMATION
−Removed: None of our directors or officers have ado pted , modified, or termi nated any trading plans under Rule 10b5-1 of the Exchange Act or any similar arrangements during the three months ended March 31, 2025.
+Added: None of our directors or officers have ado pted , modified, or termi nated any trading plans under Rule 10b5-1 of the Exchange Act or any similar arrangements during the six months ended June 30, 2025.
The exhibits listed in the accompanying index to exhibits are filed or incorporated by reference as part of this Quarterly Report.
1 unchanged sentence
Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Company’s Annual Report on Form 10-K filed with the SEC on March 15, 2024).
−Removed: Form of Series E Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the SEC on January 7, 2025).
−Removed: Form of January 2025 Wainwright Warrant (incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed with the SEC on January 7, 2025).
−Removed: Form of Series F Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the SEC on March 10, 2025).
−Removed: Form of Pre-Funded (incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed with the SEC on March 10, 2025).
−Removed: Form of March 2025 Warrant (incorporated by reference to Exhibit 4.3 to the Company’s Current Report on Form 8-K filed with the SEC on March 10, 2025).
−Removed: Form of Securities Purchase Agreement, dated as of January 6, 2025, by and among Acurx Pharmaceuticals, Inc.
−Removed: and the purchasers party thereto (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on January 7, 2025).
−Removed: Form of Securities Purchase Agreement, dated as of March 6, 2025, by and between Acurx Pharmaceuticals, Inc.
−Removed: and the purchaser party thereto (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on March 10, 2025).
+Added: Certificate of Amendment to the Certificate of Incorporation of Acurx Pharmaceuticals, Inc.
+Added: (incorporated by reference to Exhibit 3.1 to the Company’s Form 8-K filed on July 31, 2025).
+Added: Form of New G-1 Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Form 8-K filed with the SEC on June 20, 2025).
+Added: Form of New G-2 Warrant (incorporated by reference to Exhibit 4.2 to the Company’s Form 8-K filed with the SEC on June 20, 2025).
+Added: Form of Wainwright Warrant (incorporated by reference to Exhibit 4.3 to the Company’s Form 8-K filed with the SEC on June 20, 2025).
+Added: Purchase Agreement, dated as of May 8, 2025, between Acurx Pharmaceuticals, Inc.
+Added: and Lincoln Park Capital Fund, LLC (incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K filed with the SEC on May 8, 2025).
+Added: Registration Rights Agreement, dated as of May 8, 2025, between Acurx Pharmaceuticals, Inc.
+Added: and Lincoln Park Capital Fund, LLC (incorporated by reference to Exhibit 10.2 to the Company’s Form 8-K filed with the SEC on May 8, 2025).
+Added: Form of Letter Agreement (incorporated by reference to Exhibit 10.1 of the Company’s Form 8-K filed with the SEC on June 20, 2025).
Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
14 unchanged sentences
Acurx Pharmaceuticals, Inc.
+Added: August 11, 2025
President and Chief Executive Officer
(Principal Executive Officer)
+Added: August 11, 2025
/s/ Robert G.
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.